Tofersen, Phase 3 Valor Study, and Clinically Meaningful Impacts in SOD1-ALS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Tofersen, Phase 3 Valor Study, and Clinically Meaningful Impacts in SOD1-ALS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1 month ago
neurologylive.com
A minority of ALS cases are associated with SOD1 mutations. Tofersen is an antisense oligonucleotide designed to reduce SOD1 protein synthesis, but its effects in patients with ALS are unknown. New research findings are summarized in a short video. https://nej.md/3qJwaCL | The New England Journal of Medicine
2:19
A minority of ALS cases are associated with SOD1 mutations. Tofersen is an antisense oligonucleotide designed to reduce SOD1 protein synthesis, but its effects in patients with ALS are unknown. New research findings are summarized in a short video. https://nej.md/3qJwaCL | The New England Journal of Medicine
5.9K viewsSep 20, 2022
FacebookThe New England Journal of Medicine
With the recent news about Tofersen, an effective drug for SOD1 MND - we thought we'd summarise exactly what the drug is, and what the drug can do. Tofersen targets a specific change in a gene known as SOD1, which accounts for around 2% of MND cases. Watch our video below. | MND Association
1:42
With the recent news about Tofersen, an effective drug for SOD1 MND - we thought we'd summarise exactly what the drug is, and what the drug can do. Tofersen targets a specific change in a gene known as SOD1, which accounts for around 2% of MND cases. Watch our video below. | MND Association
1.4K viewsNov 21, 2024
FacebookMND Association
Tofersen Approved for SOD1-ALS
0:49
Tofersen Approved for SOD1-ALS
4.3K viewsApr 25, 2023
YouTubeThe ALS Association
ALS Breakthrough: Tofersen's Hopeful Genetic Therapy Explained #shorts
0:36
ALS Breakthrough: Tofersen's Hopeful Genetic Therapy Explained #shorts
398 views8 months ago
YouTubeNeuromuscular Medicine Expert
Tofersen, Phase 3 Valor Study, and Clinically Significant Impacts on SOD1-ALS
34:01
Tofersen, Phase 3 Valor Study, and Clinically Significant Impacts on SOD1-ALS
135 views1 month ago
YouTubeNeurologyLive
Revolutionizing ALS Treatment: The Tofersen Breakthrough
18:09
Revolutionizing ALS Treatment: The Tofersen Breakthrough
5.3K viewsMar 17, 2025
YouTubeNeurology Journal
1:13:10
Neuromuscular Rehabilitation and ALS Recovery: Update on Tofersen for ALS
1.7K views11 months ago
YouTubeEverything ALS
2:40
Tofersen helps people with ALS caused by an SOD1 mutation
3.1K viewsNov 15, 2022
YouTubeRandompile
4:28
Understanding Tofersen’s Impact on SOD1 ALS, Neurofilament Light
3.1K viewsNov 21, 2022
YouTubeNeurologyLive
Motor neurone disease: Trails suggest Tofersen injections can slow the progression of MND - The Global Herald
Oct 8, 2022
theglobalherald.com
Amyotrophic lateral sclerosis | Biogen
Apr 6, 2023
biogen.com
Clinical Trials | Biogen
Nov 15, 2022
biogen.com
0:41
För Torstein handlar livet med SMA om att vara medveten om sjukdomen – men inte låta den definiera honom. | Biogen
40.7K views4 months ago
FacebookBiogen
0:46
We’re blazing a new path forward in understanding the treatment of Multiple Sclerosis with the aim of pioneering new treatment options. Learn more about MS PATHS, our innovative efforts to change care and mobility for people living with MS: | Biogen
503 viewsJun 1, 2020
FacebookBiogen
4:04
Paula Trefiak was one of the first ALS patients to take the drug Tofersen as part of a clinical trial. The Regina resident was diagnosed with ALS in 2016 and told she only had another two to five years to live. Instead, thanks to the new drug, she's still living an active life. Her experience shows why its approval is generating so much excitement. (Reporting: Bonnie Allen/CBC; Video: Kirk Fraser/CBC; Editing: Priya Bhat/CBC) #als #health #science #canada #cbcnews
114.9K viewsMar 17, 2025
TikTokcbcsasknews
1:25
The accelerated approval of Tofersen marks the beginning of personalized treatments for ALS, a deadly neurodegenerative disease #als #medication #tiktokdoc #learnontiktok
64.4K viewsApr 26, 2023
TikTokrubin_allergy
1:31
Elizabeth F. discusses our new agreement with Siemens Healthineers to plan to develop innovative MRI tools that may lead to better assessment of brain health in multiple sclerosis. #BiogenScience | Biogen
47.5K viewsJan 27, 2017
FacebookBiogen
0:31
From day one, our student employees know the meaning of their work. Co-ops and interns get to see their impact first-hand by helping to advance important initiatives at Biogen. Hear students, their supervisors, and program advisors share their experiences. Explore our programs available to students here: https://ow.ly/gMuC50UpWVl | Biogen
407 viewsDec 12, 2024
FacebookBiogen
1:59
Shares of Biogen soared more than 40% after a surprise successful trial of its experimental Alzheimer's drug. https://reut.rs/3riqFv7 | Reuters
645.4K viewsSep 28, 2022
FacebookReuters
1:01
Through our research on the role of tau in Alzheimer’s disease, we can better understand how symptoms will present in patients and how the disease progresses. Watch more: | Biogen
312 viewsOct 25, 2023
FacebookBiogen
0:34
We’re dedicated to changing the narrative of Multiple Sclerosis (MS) and helping to improve health outcomes for underrepresented patients. To do this, we’re working with patients, research institutions, and many more so we can work toward pioneering treatments for all patients. | Biogen
711 viewsJun 23, 2020
FacebookBiogen
0:17
Struggling to sleep? 😴 According to a recent nationwide sleep survey conducted by Sloom, the average South African gets between 6h20 and 6h35 of sleep each night, which is below the recommended 7-9 hours for adults, with only 20% stating that they wake up feeling truly rested. 🛌 Introducing Biogen Magnisol Sleep. The combination of magnesium glycinate, inositol, and vitamin C helps support muscle function, maintain electrolyte balance, and support a healthy immune system while reducing oxidati
43.3K views10 months ago
FacebookBiogen
0:50
Our team is committed to making a real difference in the lives of those affected by Alzheimer’s disease. By building on research on the role of amyloid plaques and neurofibrillary tangles, we’re now making groundbreaking strides in targeting the root causes of the disease. With every research breakthrough, we’re bringing hope closer to reality for patients and families. Discover more about our ongoing efforts: https://ow.ly/cON150UQlNs | Biogen
360 viewsJan 30, 2025
FacebookBiogen
3:25
Fighting ALS at the Genetic Level: Real World Results for Tofersen
2.4K views8 months ago
YouTubeSciTube
0:25
Woven throughout our redesigned website you will find stories about the patients we serve, our people, our science, and our communities. While our look may have changed, our purpose to serve humanity through science remains the same. http://ow.ly/tF4250LHix0 | Biogen
469 viewsNov 14, 2022
FacebookBiogen
0:43
FDA Approves First Drug to Target Genetic Cause of ALS
6 viewsMay 4, 2023
DailymotionBenzinga
0:33
We’re evolving and diversifying our pipeline. Learn about our focus in immunology, neurology and rare disease. | Biogen
7.3K views7 months ago
FacebookBiogen
Careers | Biogen
Aug 2, 2018
biogen.com
Company | Biogen
Nov 2, 2020
biogen.com
See more